Evolus (EOLS) Net Equity Issued and Repurchased (2018 - 2024)

Evolus (EOLS) posted Net Equity Issued and Repurchased of $4.2 million for Q2 2024, down 91.05% on a QoQ basis from $47.0 million in Q1 2024.

Evolus (EOLS) Net Equity Issued and Repurchased (2018 - 2024) Analysis & Trends

Evolus' Net Equity Issued and Repurchased history runs 4 years deep, the most recent figure standing at $4.2 million for Q2 2024.

Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $4.2 million in Q2 2024, while the trailing twelve-month figure through Mar 2025 was $4.2 million (down 91.05% YoY) and the FY2024 annual result came in at $51.2 million, changed N/A from the prior year.
Net Equity Issued and Repurchased was $4.2 million for Q2 2024 at Evolus, down from $47.0 million in the prior quarter.
Across five years, Net Equity Issued and Repurchased topped out at $81.5 million in Q4 2021 and bottomed at $11000.0 in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn	-
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn	-
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn	-
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn	-
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn	500,000.00
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn	23.60 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn	-
10	Evolus	390.47 Mn	340.68 Mn	48.90 Mn	-

Download Data